NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · USD

bioAffinity Technologies, Inc. (BIAFW) Stock Analysis

bioAffinity Technologies, Inc. (BIAFW) is a stock listed on NASDAQ and quoted in US Dollar.

BIAFW

$0.70

+$0.31 (+79.03%)

Sep 4, 2026 · Market close

This is a derivative instrument — a warrant on bioAffinity Technologies, Inc. (BIAF) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View BIAF →

Price History

Hover for the daily close. The dotted line marks the period open.

BIAFW Key Statistics

As of Sep 4, 2026
Trading
Open
$0.47
Previous Close
$0.39
Day's Range
0.33–0.79
52-Week Range
0.33–0.79
Volume
39.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.11

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BIAFW Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+112.12%
2025 (partial year)+0.00%

As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Visit website →